Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

NCT01237808 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01237808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01237808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
Lead sponsor
University of Ulm
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
July 13, 2018
Enrollment
144 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)